Trial Profile
A Randomized, Double-blind, Crossover Study to Assess the Effects of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2017
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Essential hypertension
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals
- 15 Jun 2015 Results presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.
- 15 Jun 2015 Primary endpoint has been met. (Cumulative Sodium excretion (natriuresis) [ Time Frame: 6 hour following the first dose of LCZ696 and valsartan ]) as per abstract presented at 25th European Meeting on Hypertension and Cardiovascular Protection.
- 15 Jun 2015 Primary endpoint has been met. (Cumulative Sodium excretion (natriuresis) [ Time Frame: 24 hour following the first dose of LCZ696 and valsartan ]) as per abstract presented at 25th European Meeting on Hypertension and Cardiovascular Protection.